NTHU
16.8.2021 11:02:07 CEST | Business Wire | Press release
Due to their high energy density and low cost, metal-air batteries are one of the most promising power sources of the future. A joint Tsinghua-Liverpool research team has recently developed a new charge storage mechanism that allows rechargeability within calcium-air batteries - a major step forward in battery technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210816005031/en/
This discovery has been published in Chemical Science . The lead author of the paper, Yi-Ting Lu, is a joint doctoral student at Tsinghua and Liverpool, whose supervisors are Prof. Chi-Chang Hu (Department of Chemical Engineering, NTHU) and Prof. Laurence Hardwick (Department of Chemistry, UoL).
A major breakthrough related to Ca-air batteries
Prof. Hu said conventional lithium-ion batteries have a limited practical capacity. Thereby many researchers are working on developing alternative battery technologies. Their focus is on metal-air batteries based on zinc, lithium, sodium, potassium, calcium, magnesium, and aluminum. The advantage of the calcium-air battery is its high specific energy—five times that of traditional lithium-ion batteries. However, the feasibility of calcium-air batteries remains hampered by one major drawback—it cannot be recharged.
Lu explained that metal-air batteries are electrochemical cells usually using an active metal as the negative electrode, and a porous carbon material in contact with the air as the positive electrode. When the metal oxidized the oxygen at the positive electrode is reduced, generating electric current.
After completing his first year of doctoral studies at NTHU, Lu enrolled at the Stephenson Institute for Renewable Energy at UoL in September 2018. Under the supervision of Prof. Hardwick, he began doing research on the electrolyte used in calcium-air batteries.
Lu found when a single electrode is repeatedly charged and discharged, initially no reversibility can be observed, but after a few dozen cycles it gradually displays some reversibility. Surprisingly, the result seemed completely different from those in literature. The research team conducted a series of experiments aimed at uncovering the mechanism behind this phenomenon. On the electrode surface, the discharge products form a calcium oxide (Cax Oy ) interlayer, where the discharge product of oxygen, known as superoxide, is confined, allowing the superoxide to be then readily oxidized. This suggests the oxygen could probably be repeatedly oxidized/reduced, so that the cell can be continuously discharged/recharged.
Dr. Alex Neale, a Liverpool postdoctoral researcher, who is also part of the research team, said that through systematic electrochemical and spectroscopy investigations, the team began to understand the origins of this charge storage mechanism that facilitates a previously unseen degree of reversibility for systems based on the calcium-air battery.
Prof. Hardwick said the team will focus on designing new battery systems that use this newly discovered charge storage mechanism. He added that it was the cooperative research that made their discovery possible, and there are plans for even closer cooperation between NTHU and UoL in the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210816005031/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
